Company intelligence / Profile preview
NeoCura
Beijing, Beijing, Chinaneocura.net ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Lead asset XH‑001, an mRNA-based tumor neoantigen vaccine, has entered Phase II trials for advanced solid tumors. Multiple first-in-class R&D pipelines are ongoing, with a focus on personalized cancer immunotherapies and virus vaccines. Early clinical results have enabled expansion into additional indications and partnerships with global biotech firms.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA vaccinessiRNA therapeuticsTherapeutic vaccinesProphylactic vaccinesPersonalized antigen vaccine
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
MDimune Inc. – collaboration on CDV-mediated delivery of mRNA therapeutics using the BioDrone® platform for oncology applications.PhoreMost Limited – research collaboration to explore novel cancer therapeutics using complementary technologies from both companies.
Beyond the preview
Go deeper on NeoCura.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoCura.